scPharmaceuticals Inc. (SCPH)
scPharmaceuticals Statistics
Share Statistics
scPharmaceuticals has 50.04M shares outstanding. The number of shares has increased by 39.47% in one year.
| Shares Outstanding | 50.04M |
| Shares Change (YoY) | 39.47% |
| Shares Change (QoQ) | 0.49% |
| Owned by Institutions (%) | 85.39% |
| Shares Floating | 34.26M |
| Failed to Deliver (FTD) Shares | 3.5K |
| FTD / Avg. Volume | 0.83% |
Short Selling Information
The latest short interest is 6.27M, so 12.54% of the outstanding shares have been sold short.
| Short Interest | 6.27M |
| Short % of Shares Out | 12.54% |
| Short % of Float | 18.16% |
| Short Ratio (days to cover) | 14.21 |
Valuation Ratios
The PE ratio is -1.85 and the forward PE ratio is -3.03. scPharmaceuticals's PEG ratio is -0.05.
| PE Ratio | -1.85 |
| Forward PE | -3.03 |
| PS Ratio | 4.34 |
| Forward PS | 0.4 |
| PB Ratio | 11.83 |
| P/FCF Ratio | -2.23 |
| PEG Ratio | -0.05 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for scPharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.12, with a Debt / Equity ratio of 3.96.
| Current Ratio | 7.12 |
| Quick Ratio | 6.18 |
| Debt / Equity | 3.96 |
| Debt / EBITDA | -0.68 |
| Debt / FCF | -0.75 |
| Interest Coverage | -8.56 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $224.27K |
| Profits Per Employee | $-525.6K |
| Employee Count | 162 |
| Asset Turnover | 0.34 |
| Inventory Turnover | 0.82 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -52.21% in the last 52 weeks. The beta is 0.39, so scPharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.39 |
| 52-Week Price Change | -52.21% |
| 50-Day Moving Average | 3.18 |
| 200-Day Moving Average | 3.98 |
| Relative Strength Index (RSI) | 32.56 |
| Average Volume (20 Days) | 419.67K |
Income Statement
In the last 12 months, scPharmaceuticals had revenue of 36.33M and earned -85.15M in profits. Earnings per share was -1.91.
| Revenue | 36.33M |
| Gross Profit | 24.97M |
| Operating Income | -64.78M |
| Net Income | -85.15M |
| EBITDA | -77.56M |
| EBIT | -77.58M |
| Earnings Per Share (EPS) | -1.91 |
Balance Sheet
The company has 75.66M in cash and 52.69M in debt, giving a net cash position of 22.96M.
| Cash & Cash Equivalents | 75.66M |
| Total Debt | 52.69M |
| Net Cash | 22.96M |
| Retained Earnings | -366.49M |
| Total Assets | 107.52M |
| Working Capital | 90.97M |
Cash Flow
In the last 12 months, operating cash flow was -70.54M and capital expenditures -21K, giving a free cash flow of -70.56M.
| Operating Cash Flow | -70.54M |
| Capital Expenditures | -21K |
| Free Cash Flow | -70.56M |
| FCF Per Share | -1.58 |
Margins
Gross margin is 68.73%, with operating and profit margins of -178.29% and -234.36%.
| Gross Margin | 68.73% |
| Operating Margin | -178.29% |
| Pretax Margin | -234.36% |
| Profit Margin | -234.36% |
| EBITDA Margin | -213.47% |
| EBIT Margin | -178.29% |
| FCF Margin | -194.21% |
Dividends & Yields
SCPH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for SCPH is $12, which is 381.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $12 |
| Price Target Difference | 381.9% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | -5.05 |
| Piotroski F-Score | 3 |